Bluebird Falls as Operating Costs Soar Amid Biotech Selloff

Updated on

Bluebird Bio Inc., which is developing gene therapies for rare diseases and cancer, fell after reporting a wider loss than analysts had estimated amid a selloff in biotechnology stocks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.